Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine

The prevalence of preexisting immunity to adenoviruses in the majority of the human population might adversely impact the development of adaptive immune responses against adenovirus vector-based vaccines. To address this issue, we primed BALB/c mice either intranasally (i.n.) or intramuscularly (i.m.) with varying doses of wild type (WT) human adenovirus subtype 5 (HAd5). Following the development of immunity against HAd5, we immunized animals via the i.n. or i.m. route of inoculation with a HAd vector (HAd-HA-NP) expressing the hemagglutinin (HA) and nucleoprotein (NP) of A/Vietnam/1203/04 (H5N1) influenza virus. The immunogenicity and protection results suggest that low levels of vector immunity (<520 virus-neutralization titer) induced by priming mice with up to 107 plaque forming units (p.f.u.) of HAd-WT did not adversely impact the protective efficacy of the vaccine. Furthermore, high levels of vector immunity (approximately 1500 virus-neutralization titer) induced by priming mice with 108 p.f.u. of HAd-WT were overcome by either increasing the vaccine dose or using alternate routes of vaccination. A further increase in the priming dose to 109 p.f.u. allowed only partial protection. These results suggest possible strategies to overcome the variable levels of human immunity against adenoviruses, leading to better utilization of HAd vector-based vaccines.

• Publication year

  2012

• Venue

  PLoS ONE

• Publication date

  2012-03-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1371/journal.pone.0033428PMID 22432020PMCID 3303828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Production of adenovirus vectors and their use as a delivery system for influenza vaccines

  2010cited by this paper
• Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model.

  2010cited by this paper
• International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.

  2010cited by this paper
• Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8+ T Lymphocytes

  2010cited by this paper
• Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive.

  2010cited by this paper
• Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice

  2008cited by this paper
• A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

  2008cited by this paper
• Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.

  2008cited by this paper
• Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent Pathways

  2007cited by this paper
• New Pre‐pandemic Influenza Vaccines: An Egg‐ and Adjuvant‐independent Human Adenoviral Vector Strategy Induces Long‐lasting Protective Immune Responses in Mice

  2007cited by this paper
• Cell-mediated Protection in Influenza Infection

  2006cited by this paper
• Mucosal vaccines: the promise and the challenge

  2006cited by this paper
• Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

  2006cited by this paper
• Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization

  2006cited by this paper
• Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis.

  2006cited by this paper
• Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

  2006cited by this paper
• Adenovirus Vector-Based Vaccines for Human Immunodeficiency Virus Type 1

  2005cited by this paper
• Development of nonhuman adenoviruses as vaccine vectors

  2005cited by this paper
• Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture.

  2005cited by this paper
• Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

  2005cited by this paper
• Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States

  2004cited by this paper
• Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

  2004cited by this paper
• Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture.

  2004cited by this paper
• Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

  2004cited by this paper
• Vectors

  2003cited by this paper
• Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

  2003cited by this paper
• Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System

  2003cited by this paper
• Effects of a SARS-associated coronavirus vaccine in monkeys

  2003cited by this paper
• Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

  2003cited by this paper
• Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines.

  2002cited by this paper
• DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

  2002cited by this paper
• Development and Characterization of Bovine × Human Hybrid Cell Lines That Efficiently Support the Replication of both Wild-Type Bovine and Human Adenoviruses and Those with E1 Deleted

  2002cited by this paper
• Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration.

  2001cited by this paper
• A Mouse Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated from Humans

  1999cited by this paper
• A High-Efficiency Cre/loxP-Based System for Construction of Adenoviral Vectors

  1999cited by this paper
• Enhanced antibody and cytokine responses to influenza viral antigens in perforin-deficient mice.

  1998cited by this paper
• Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.

  1996cited by this paper
• High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model.

  1995cited by this paper
• Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter.

  1993cited by this paper
• Influenza: pathogenesis and host defense.

  1992cited by this paper
• Influenza: pathogenesis and host defense.

  1992cited by this paper
• Influenza: pathogenesis and host defense.

  1990cited by this paper
• Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus.

  1989cited by this paper
• Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

  1977cited by this paper

• Current Landscape and Domestic Breakthroughs: A Comprehensive Review of Pet Vaccines in China

  2026cites this paper
• A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants

  2025cites this paper
• The Design and Prospects of Influenza Virus Vaccines Based on Conserved Epitopes and Adjuvant Optimization

  2025cites this paper
• Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2

  2025cites this paper
• Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein

  2025cites this paper
• The frequency and function of nucleoprotein-specific CD8+ T cells are critical for heterosubtypic immunity against influenza virus infection

  2024cites this paper
• Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches

  2024cites this paper
• An Old Acquaintance: Could Adenoviruses Be Our Next Pandemic Threat?

  2023cites this paper
• Enhancement of mucosal innate and adaptive immunity following intranasal immunization of mice with a bovine adenoviral vector

  2023influential citation
• Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines

  2023cites this paper
• Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenoviral vectored SARS-CoV-2 vaccine expressing the spike protein

  2023cites this paper
• Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine

  2023cites this paper
• Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors

  2023cites this paper
• Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.

  2023cites this paper
• Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

  2022cites this paper
• Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy

  2022cites this paper
• Vaccines platforms and COVID-19: what you need to know

  2022cites this paper
• Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview

  2022cites this paper
• A Historical Review of Brain Drug Delivery

  2022cites this paper
• COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine

  2022cites this paper
• Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes

  2021cites this paper
• Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance

  2021cites this paper
• Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice

  2021cites this paper
• A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity

  2021cites this paper
• Advances in Development and Application of Influenza Vaccines

  2021cites this paper
• An overview of current COVID-19 vaccine platforms

  2021cites this paper
• Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?

  2021cites this paper
• Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses

  2021cites this paper
• Immunologic Dose-Response to Adenovirus-Vectored Vaccines in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral Vaccine Vectors when Given via an Intramuscular or Subcutaneous Route

  2020cites this paper
• Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines

  2020cites this paper
• The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

  2020cites this paper
• Response Type and Host Species may be Sufficient to Predict Dose-Response Curve Shape for Adenoviral Vector Vaccines

  2020cites this paper
• Recombinant Adenovirus Vectors as Mucosal Vaccines

  2020cites this paper
• Current Use of Adenovirus Vectors and Their Production Methods.

  2019cites this paper
• Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model

  2019cites this paper
• Promising Cytomegalovirus-Based Vaccine Vector Induces Robust CD8+ T-Cell Response

  2019cites this paper
• Generation of infectious clone of bovine adenovirus type I expressing a visible marker gene.

  2018cites this paper
• Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.

  2018influential citation
• 31 – Inactivated Influenza Vaccines

  2018cites this paper
• A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose

  2018cites this paper
• IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo

  2017cites this paper
• Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses

  2017cites this paper
• Evaluating the promise of recombinant transmissible vaccines

  2017cites this paper
• A highly immunogenic vaccine against A/H7N9 influenza virus.

  2016cites this paper
• Vaccines for the prevention against the threat of MERS-CoV

  2016cites this paper
• Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon

  2016cites this paper
• Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.

  2016cites this paper
• Antibodies against Adenoviruses

  2016cites this paper
• Vaccines against influenza A viruses in poultry and swine: Status and future developments.

  2015cites this paper
• Adenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice

  2015cites this paper
• Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice

  2015cites this paper
• Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection

  2015cites this paper
• Nasal and pulmonary vaccine delivery using particulate carriers

  2015cites this paper
• Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Development of universal influenza vaccines based on influenza virus M and NP genes

  2014cites this paper
• Adenovirus-based vaccines against avian-origin H5N1 influenza viruses

  2014cites this paper
• Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.

  2014cites this paper
• A Highly Sensitive Europium Nanoparticle-Based Immunoassay for Detection of Influenza A/B Virus Antigen in Clinical Specimens

  2014cites this paper
• CD40L Gene Therapy for Solid Tumors

  2014cites this paper
• Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

  2013cites this paper
• Pre-existing immunity against vaccine vectors – friend or foe?

  2013cites this paper
• Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness

  2013cites this paper
• 17 – Inactivated influenza vaccines

  2013cites this paper
• The role of dendritic cells in adjuvant-induced immune responses

  2013cites this paper
• Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development.

  2013cites this paper
• Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice.

  2013cites this paper
• Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.

  2013cites this paper
• Adenoviral Vectors in Veterinary Vaccine Development: Potential for Further Development

  2013cites this paper
• CÔNG NGHADENOVIRUS VECTOR VÀ NG DNG TRONG KÍCHNG MIN DCH GIA CM

  2012cites this paper
• Recombinant Influenza Vaccines

  2012cites this paper
• Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines

  2012cites this paper
• Vaccine development for protecting swine against influenza virus

  2012cites this paper
• Studies on influenza virus replicon particle vaccines in pigs

  2012cites this paper
• An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models

  2012cites this paper
• Multi-scale photoacoustic tomography and its applications to cancer research

  2012cites this paper